NR3C1 and depressive symptom measurement: Currently, the possibility of using drugs that reduce the activity of HPAA (antagonists of CRH receptors and glucocorticoid receptors, inhibitors of glucocorticoid synthesis) for the treatment of depression is being investigated [184,185].